Novo Nordisk
NVO
#35
Rank
ยฃ207.95 B
Marketcap
ยฃ47.16
Share price
2.17%
Change (1 day)
-53.42%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : ยฃ33.86 Billion

According to Novo Nordisk's latest financial reports the company's total liabilities are ยฃ33.86 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novo Nordisk - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31ยฃ35.83 B48.26%
2023-12-31ยฃ24.17 B28.71%
2022-12-31ยฃ18.78 B34.54%
2021-12-31ยฃ13.95 B41.07%
2020-12-31ยฃ9.89 B27.23%
2019-12-31ยฃ7.77 B9.34%
2018-12-31ยฃ7.11 B13.49%
2017-12-31ยฃ6.26 B4.49%
2016-12-31ยฃ5.99 B35.29%
2015-12-31ยฃ4.43 B14.93%
2014-12-31ยฃ3.85 B23.76%
2013-12-31ยฃ3.11 B13.47%
2012-12-31ยฃ2.74 B-10.07%
2011-12-31ยฃ3.05 B8.11%
2010-12-31ยฃ2.82 B24.85%
2009-12-31ยฃ2.26 B-0.04%
2008-12-31ยฃ2.26 B47.57%
2007-12-31ยฃ1.53 B16.33%
2006-12-31ยฃ1.31 B0.41%
2005-12-31ยฃ1.31 B25.81%
2004-12-31ยฃ1.04 B20.08%
2003-12-31ยฃ0.86 B11.21%
2002-12-31ยฃ0.78 B-11.53%
2001-12-31ยฃ0.88 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
ยฃ94.05 B 177.72%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ48.52 B 43.29%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ57.39 B 69.47%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ43.05 B 27.13%๐Ÿ‡ซ๐Ÿ‡ท France